KFF November 4, 2024
Elizabeth Williams, Robin Rudowitz, Clea Bell

GLP-1 (glucagon-like peptide-1) drugs have been used as a treatment for type 2 diabetes for over a decade, but newer forms of these drugs have gained widespread attention for their effectiveness as a treatment for obesity. While these drugs have provided new opportunities for obesity treatment, they have also raised questions about access to and affordability of these drugs. These drugs are expensive when purchased out of pocket, and coverage in Medicaid, ACA Marketplace plans, and most large employer firms remains limited, though a number of state Medicaid programs and other payers are re-evaluating their coverage policies. Expanding Medicaid coverage of these drugs could increase access for the almost 40% of adults and 26% of children with obesity in Medicaid....

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Insurance, Medicaid, Pharma / Biotech
Redesigning Integrated Care For Dually Eligible People With Intellectual/Developmental Disabilities
Medicaid spending on weight loss, diabetes drugs up 500% since 2019: 5 numbers to know
CMS Launches New Program for Mental Health, OUD Treatment
Georgia Medicaid shakeup could force 3 in 4 beneficiaries to change plans: Centene CEO
New Center to Coordinate Between Medicaid, Maternal and Child Health

Share This Article